Welcome to our dedicated page for Beyondspring SEC filings (Ticker: BYSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BeyondSpring Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on cancer therapies, including Plinabulin development, financial results and capital structure. Its Form 10-K and Form 8-K disclosures cover audited consolidated financial statements, quarterly and annual operating results, clinical-program updates, and risk and business information tied to oncology development.
Current reports also record material agreements, registered offerings of ordinary shares, SEED Therapeutics financing and ownership disclosures, and shareholder-vote results from annual meetings. These filings describe governance actions, securities issuances, registration-statement use and other material events affecting BeyondSpring’s public-company reporting.
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on its lead asset Plinabulin and a TPD platform carried through SEED. As of June 30, 2025 the consolidated balance sheet shows $31.0 million in total assets and $48.6 million in total liabilities, resulting in a $17.5 million shareholders' deficit (including noncontrolling interests). Cash and cash equivalents from continuing operations increased to $9.544 million.
Operationally, the company reported a consolidated net loss of $4.65 million for the quarter ended June 30, 2025 and a $3.48 million net loss for the six months. For the six months ended June 30, 2025, however, net income attributable to BeyondSpring Inc. was $2.671 million, which reflects a $6.986 million gain recognized on the first closing of the sale of subsidiary interests in SEED. The company completed a first closing that generated $7.354 million of cash proceeds and recorded gross proceeds from the multi-tranche sale agreements of approximately $35.418 million.
Cash flow activity shows $10.07 million used in operating activities and $17.15 million provided by investing activities (including maturities of short-term investments and proceeds from the SEED sale), producing a $7.08 million net increase in cash for the six months. Significant off-balance-sheet and contract items disclosed include $31.039 million upfront consideration received under the Hengrui collaboration that remains recorded as deferred revenue and a full valuation allowance on deferred tax assets with $4.573 million of gross unrecognized tax benefits.
BeyondSpring Inc. filed a current report to note that it released a press release with its financial results for the quarter ended June 30, 2025. The company furnished this press release as an exhibit, meaning it is made available for investors’ information but is not treated as part of the company’s formally "filed" financial statements under securities laws. The filing also confirms that BeyondSpring’s ordinary shares continue to trade on The NASDAQ Stock Market under the symbol BYSI.
Decheng Capital-affiliated entities reported a series of open-market sales of BeyondSpring Inc. (BYSI) ordinary shares between 06/17/2025 and 08/04/2025. The Form 4 shows multiple dispositions totaling 394,436 shares sold across the reported dates at prices ranging from $3.23 down to $2.18. Footnotes note weighted-average prices and price ranges for specific blocks ($3.10–$3.34, $3.05–$3.27, $3.06–$3.19) and state the reporters will provide per-price details on request. Despite these sales, the filing shows that Decheng Capital China Life Sciences USD Fund III, L.P. continues to beneficially own 1,979,072 shares (indirect), and related Decheng entities and managers disclaim direct ownership except to the extent of pecuniary interest.
Decheng Capital and related funds disclosed initial beneficial ownership in BeyondSpring Inc. (BYSI). Three Decheng-managed funds report indirect holdings of 1,979,072, 1,903,579 and 1,000,000 ordinary shares respectively. The filings indicate indirect ownership through general partner entities and identify Dr. Xiangmin Cui as manager with disclaimers of ownership except for pecuniary interest. No derivative securities are reported.